N
Neurocrine Biosciences, Inc.
NBIX · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Monopoly Cash Machine Funding a Pipeline the Market Thinks Is Worthless
The market has re-rated this from a hyper-growth darling to a maturing single-drug story and is pricing the pipeline at essentially zero — but CRENESSITY's trajectory and 2027's MDD readout could simultaneously prove that the second and third acts are real, which would make the current multiple look absurd in retrospect.
Flowly Score
Apr 16 Close
+173%$128.41
Fair Value
$350.00
72
Strongat $128.41
Business Strength7/10
INGREZZA is a genuine regulatory monopoly with real switching costs and near-perfect unit economics, but a single-product specialty pharma — no matter how dominant — deserves a structural discount for concentration; CRENESSITY's first-year momentum is the first credible evidence this might become a platform rather than a franchise.
Financial Resilience8/10
This is as close to a royalty stream as you'll find wearing a pharmaceutical costume — asset-light, minimal capex, and cash consistently outrunning reported earnings by a wide margin, with a balance sheet that has flipped from cautious to fortress-grade as buybacks and cash accumulation accelerate simultaneously.
Growth & Trajectory7/10
INGREZZA's deceleration from blockbuster-growth to steady-compounder is structural and expected, but CRENESSITY clearing triple-digit millions in its first year while management describes it as still early — with 90% of target patients untreated — suggests the second growth engine is igniting faster than consensus priced in.
Valuation8/10at $129.93
A multiple that has compressed from the stratosphere to reasonable while the underlying business became structurally stronger — higher margins, cleaner cash conversion, a second product — is one of the more reliable setups in specialty pharma; even a conservative DCF implies the current price embeds near-certain franchise decay that the operating data simply doesn't support.
Risk4/10
Single-product concentration is the unambiguous dominant risk — if INGREZZA stumbles through competitive pressure, patent challenge, or a structural decline in TD incidence, there is no second pillar large enough to absorb the blow yet; the CNS pipeline is real optionality but sits in the industry's most brutal killing field for drug development.
The investment case rests on a genuine tension: a business with exceptional unit economics and accelerating cash generation trading at a multiple that implies competitive decay is imminent. The P/E compression narrative creates a value trap illusion — the business is actually better today than when it traded at twice the multiple. FCF yields at these levels for a near-monopoly drug with a decade of patent runway are unusual, and the market appears to be discounting the INGREZZA runway as if 2027 is 2034. The trajectory story is quietly becoming more interesting than the headline numbers suggest. INGREZZA's volume growth remains double-digit even as pricing concessions weigh on net sales — the underlying patient demand is durable, not fading. More importantly, CRENESSITY has cleared the first credible milestone for a second franchise: a nascent prescriber base, a concentrated patient population, and management comparing the ramp favorably to INGREZZA's own early years. The 2027 pipeline readouts in MDD and schizophrenia are genuinely binary events that the market has assigned near-zero probability — which is rational given CNS history, but means any signal of efficacy would be unpriced. The single biggest specific risk is not generic competition or pricing pressure — it is a coordinated failure: INGREZZA facing an earlier-than-expected patent challenge while the MDD program produces a null result in Phase 3. That combination would leave a business with decelerating primary revenue, no credible successor, and a cash pile that quickly looks insufficient against the restructuring required. CNS drug development has produced exactly this outcome for many companies that seemed well-positioned at similar stages, and the base rate of Phase 3 CNS failure should command genuine humility from anyone modeling a pipeline-dependent bull case.